Airfinity RSV Intelligence (1)

Airfinity's RSV intelligence solution includes independent analysis and forecasts across all candidates in clinical development and post-approval.

As the RSV market continues to develop rapidly, Airfinity is committed to continued expansion of its data and intelligence coverage. In response to recent approvals, we have added data around eligible populations in each country, as well as pricing and reported revenues for the approved candidates.

Eligible Population: Understand where RSV candidates have gained approval and which populations are eligible to receive these newly approved vaccines and prophylactics. This expanded functionality allows you to:

→ Identify which markets RSV candidates have gained approval in

→ See how the eligible populations in each market differs

→ Compare the timelines of approvals in different markets

→ Understand nuances of approvals and roll-out with extra information provided e.g. shared decision making

Pricing Data: Access all publicly available pricing data across vaccines and prophylactics including public and private pricing across markets, income bands and regions. This allows you to compare pricing data across market, region, income band, country and candidate

Revenue Data: Q3 revenue data has recently been released for the first time from Sanofi for Nirsevimab, and from GSK and Pfizer for their RSV vaccines. These new reported revenue figures are now available on the platform, alongside previous reported revenues for Palivizumab. These will continue to be tracked and updated as new revenue data is released.

Get in touch to book your free demo!

Airfinity is also monitoring and collecting supply data, this will be represented on the platform in the coming weeks. Get your sneak preview by booking your demo now.

Science360 Laptop Mock Image

Get in touch to book your free demo!

Airfinity is also monitoring and collecting supply data, this will be represented on the platform in the coming weeks. Get your sneak preview by booking your demo now.

Analysis & Insights

The rising threat of deadly diseases jumping from animals to humans
The rising threat of deadly diseases jumping from animals to humans

Read More →


More from Airfinity

Airfinity Wins FT Tech Champions 2023

Airfinity Wins Bloomberg Top 25 UK Startups to Watch

What other conditions could weight-loss drugs treat?

Global surge in infectious diseases as over 40 countries report outbreaks 10-fold over pre-pandemic levels

The West should be on a war footing for the next pandemic

Democracies are better at managing pandemics than autocracies, according to a new study by Airfinity

View All →

In the News

The future of weight loss drugs: gummies, tablets and melt-in-the-mouth strips

The i Paper | Mar 28, 2025

Value of investment on NCDs: Impact on health outcomes in low- and middle-income countries

IFPMA | Mar 11, 2025

Record Stomach Flu Outbreaks in India Show Lurking Health Risks

Bloomberg | Feb 19, 2025

Rapid trials prompt deals rush for Chinese ‘super me-too’ drugs

Financial Times | Feb 6, 2025

View All →